Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
51 participants
OBSERVATIONAL
2007-08-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lp-PLA2 and Coronary Atherosclerosis in Humans
NCT01557088
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
NCT05009862
L-Arginine in the Treatment of Peripheral Arterial Disease
NCT00284076
Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease
NCT02388971
Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis
NCT01321476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No Aspirin Treatment
No ASA
Alternative antiplatelet therapy instead of aspirin
81 mg Aspirin Treatment
Low dose ASA
Low dose aspirin (81mg) prior to PTCA
325 mg Aspirin
325 mg ASA
high dose of aspirin prior to PTCA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No ASA
Alternative antiplatelet therapy instead of aspirin
Low dose ASA
Low dose aspirin (81mg) prior to PTCA
325 mg ASA
high dose of aspirin prior to PTCA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or
2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or
3. No aspirin therapy at all
* Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA
* Patients with stable angina or positive stress tests scheduled for a cardiac catheterization
Exclusion Criteria
* Uncontrolled hypertension (SBP \> 180, DBP \>100)
* History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.
* Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Garret FitzGerald, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Wenliang Song, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
American Heart Association
Identifier Type: -
Identifier Source: secondary_id
804975
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.